FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study)
Cancer Diagnosis & Prognosis2022Vol. 2(1), pp. 101–106
Citations Over Time
Yukimasa Hatachi, Sharad R Mohan, Takeshi Kotake, Hironaga Satake, Yoshihiro Okita, Hisateru Yasui, Akihito Tsuji
Abstract
The optimum dose of FOLFIRINOX was a dosage combination of oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , l-leucovorin 400 mg/m 2 and 5-FU 2,400 mg/m 2 , administered as a continuous 46-h infusion.
Related Papers
- → FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study(2021)9 cited
- → Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer(2002)18 cited
- → FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study)(2022)2 cited
- [FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].(2019)
- → The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients(2005)3 cited